Biopharmaceutical drug discovery and development company, Evonetix, is the latest company to move to Chesterford Research Park where they join major bioscience players such as AstraZeneca, Illumina Inc and Domainex who have all chosen Chesterford as the base from which to advance their research and development.
Evonetix is the third life sciences company INVEST Essex have assisted to take space at Chesterford Research Park.
“I am personally delighted to be back at Chesterford, having been CEO at Solexa; pioneers of next-generation sequencing and a previous occupier at the Park that eventually went on to become part of Illumina. Our CSO, Joe Brennan, was also part of the Solexa team and we have enjoyed a long and successful association with Chesterford and one which we look forward to continuing as we develop Evonetix.”
Nick McCook, CEO, Evonetix
Evonetix, a spinout from Cambridge Consultants, Cambridge’s largest and oldest contract research and development (R&D) company, was founded in late 2015. The company focuses on developing a novel method of manufacturing synthetic DNA molecules with high accuracy, using a microchip-based array. Accurate DNA synthesis is important at many stages of drug discovery and development, because…
- It helps researchers to understand the mechanism of a disease in different patients and how a drug interacts with it
- It allows cells to be engineered so they actually become manufacturing units for biopharmaceuticals
- It allows cell-based assays to be developed for accurate prediction of responses to a drug
Investors first project in Essex
Evonetix worked with INVEST Essex to find suitable premises, two suites within the Science Village, an innovative, energy efficient building offering individual research and development (R&D) suites from 1,515 sq ft to 1,993 sq ft.
Evonetix are backed by Amadeus Capital Partners, the venture capital (VC) company founded by Hermann Hauser, who has successfully been involved with previous investments such as ARM, Cambridge Silicon Radio, Xaar, Domino Printing Sciences and Solexa. This is the first Amadeus Capital Partners investment to be located in Essex.
Offering space and facilities for research and development
Chesterford Research Park is a highly attractive proposition to companies in the pharmaceutical, MedTech and healthcare industries. The Research Park is a 250 acre business park set in landscaped parkland with a focus on life sciences. It offers ultra-modern and energy efficient advanced laboratory and office space with facilities developed for biotechnology and pharmaceutical companies of all sizes and a variety of sites are available for new laboratory and research and development buildings.
Chesterford Research Park was chosen by Evonetix for…
- The advantages it offers expanding life science companies
- Its close proximity to the Cambridge medical technology (MedTech) cluster
- The opportunity to work alongside major players in the bioscience industry who have also chosen Chesterford as the base from which to advance their research and development
- Its excellent access to London as well as strong connections to the rest of the UK and Europe
Rate relief and INVEST Essex Support
INVEST Essex worked with Evonetix on their choice of site and introduced them to Uttlesford District Council who were able to provide support to Evonetix with their Business Development Rate Relief Scheme. INVEST Essex project managed the application process with Uttlesford District Council. INVEST Essex continue to work with Evonetix offering skills support.
For more information on INVEST Essex see here.
For more information on Chesterford Research Park see here.
For more information on Evonetix see here.
Source [Chesterford Research Park]